CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This ...

The early stage company is developing a new approach to gene editing to treat rare genetic diseases. It does this using mRNA, ...

Editas Medicine ( (EDIT) ) has provided an announcement. Editas Medicine announced new in vivo preclinical proof of concept data and outlined its strategic priorities and key milestones for 2025, ...

New study reveals that TLE6 protein deficiency causes male infertility in mice. These findings suggest potential genetic ...

Kansas State University researchers have reported a breakthrough in developing wheat-based foods that contain lower amounts ...

Zhang, an MIT professor and a pioneer in gene-editing ... year. CRISPR-Cas9 technology – which allows scientists to precisely cut and modify DNA at specific locations within a genome – was ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...

Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) from Overweight to Equal-Weight. Analyst Price Forecast Suggests 449.14% ...

2025-2027 Strategic Priorities Financial Items As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome ...